LDLR and cardiovascular disorder: Proprotein convertase subtilisin/kexin 9 (PCSK9) plays a crucial role in lipid metabolism through its ability to degrade low-density lipoprotein receptors (LDLR), leading to increases in circulating LDL, and greater incidence of cardiovascular disease (CVD).1